OptimizeRx Corporation

OptimizeRx Corporation

OPRXNYSE / NASDAQHealthcareSmall cap

$6.70-$0.31 (-4.4%)

Last close · Data as of Nov 20, 2026

Market cap
$101.0M
P/E
19.7x
EV / EBITDA
6.3x
Revenue
$109.4M
Net margin
4.7%
ROCE
7.7%

-50.7% over the last year

OptimizeRx Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-25.0%
3M
-15.8%
6M
+34.8%
1Y
-50.7%
5Y
-90.7%

52-week range

Day change -$0.31 (-4.4%) from $7 to $7 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in OPRX, bought on each weekday since 2021.

News & filings

What OptimizeRx filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity rose from -17.2% to 4.0% between fiscal 2024 and fiscal 2025.

Concerns (1)

  • The price fell as much as 71% from a high within the last year.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

OptimizeRx Corporation operates as a digital healthcare technology company.

Read moreShow less

OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Shares outstanding
18.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$101.0M
P/E
19.7x
P/B
0.8x
EV / EBITDA
6.3x
EV / Sales
0.9x
P/S
0.9x
52-week high
$15.39
52-week low
$4.54

Profitability

Operating margin
11.0%
Net margin
4.7%
EBITDA margin
15.1%
ROE
4.0%
ROCE
7.7%
ROIC
6.9%
ROA
2.9%
Asset turnover
0.62

Growth

Revenue
$109.4M
Revenue growth, 1Y
18.8%
Revenue CAGR, 3Y
20.6%
Net profit growth, 1Y
-125.5%
Free cash flow
$18.7M

Solvency

Current ratio
3.04
Debt / Equity
0.20
Debt / Assets
0.15
CFO / Net profit
3.65
Cash / Market cap
23.1%

Where the revenue went

Of every $100 of FY2025 revenue, $5 was left as net income.

OptimizeRx Corporation income statement flow, FY2025
OptimizeRx Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$35.8M
RevenueGross profit$73.6M
Gross profitSelling, general and administrative$57.2M
Gross profitOther operating expenses$4.3M
Gross profitOperating income$12.1M
Operating incomePretax income$7.0M
Operating incomeInterest and other expense$5.1M
Pretax incomeTax and other$1.8M
Pretax incomeNet income$5.1M

Revenue and net profit

Revenue grew 18.8% in FY2025; net profit is the dashed line.

OptimizeRx Corporation revenue and net profit by fiscal year
OptimizeRx Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$62.5M-$11.4M
FY2023$71.5M-$17.6M
FY2024$92.1M-$20.1M
FY2025$109.4M$5.1M

Cash flows

FY2025: $18.7M from operations, $18.7M free after investment (dashed).

OptimizeRx Corporation operating and free cash flow by fiscal year
OptimizeRx Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$10.7M$10.4M
FY2023-$7.2M-$8.1M
FY2024$4.9M$4.4M
FY2025$18.7M$18.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$109.4M+18.8%1Y
EBITDA
$16.6M
Net profit
$5.1M
Cash from operations
$18.7M+282.8%1Y
Free cash flow
$18.7M+321.6%1Y
Revenue CAGR, 3Y
20.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$109.4M$16.6M$5.1M$18.7M4.0%+18.8%-125.5%

Monthly returns

Month-by-month returns of OPRX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$176.9M
Liabilities$48.6M
Equity$128.3M
Paid-in capital$207.5M
Retained earnings-$79.2M
Treasury stock$0.00

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; OPRX highlighted.

P/E against peers

OPRX trades at 19.7x earnings against a peer median of -1.5x.

  1. OptimizeRx Corporation (this company)19.7x

Not shown (no positive earnings and no EV / Sales): Aldeyra Therapeutics, Inc., Aardvark Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
OptimizeRx CorporationOPRXthis company$101.0M19.7x0.8x4.0%6.3x
The Joint Corp.JYNT$117.3M40.3x7.8x19.3%118.2x
Aldeyra Therapeutics, Inc.ALDX$106.2M-3.1x2.4x-76.5%-1.6x
Cardiff Oncology, Inc.CRDF$106.0M-2.3x2.3x-101.0%-1.9x
Neuronetics, Inc.STIM$101.6M-2.6x4.5x-174.3%-5.8x
Definitive Healthcare Corp.DH$95.7M-0.7x0.3x-49.4%-0.7x
Heron Therapeutics, Inc.HRTX$91.5M—6.4x-141.0%—
Outset Medical, Inc.OM$87.7M-1.1x0.7x-64.3%-2.5x
Aardvark Therapeutics, Inc.AARD$86.0M-1.5x0.8x-54.0%-0.6x
Peer median—-1.5x2.4x-70.4%-1.6x

Year-to-date ROI

OPRX since 1 January, against earlier years.

Historical volatility

OPRX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

OptimizeRx Corporation operating margin by fiscal year
OptimizeRx Corporation operating margin by fiscal year
DateOperating margin
FY2022-19.7%
FY2023-24.5%
FY2024-6.8%
FY202511.0%
LineFY2025
Cost of revenueCost Of Revenue$35.8M
Gross profitGross Profit$73.6M
Operating expensesOperating Expense$61.5M
Other operating expensesOther Operating Expenses—
Depreciation and amortisationDepreciation And Amortization In Income Statement$4.3M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$4.3M
Total expensesTotal Expenses$97.4M
Pretax incomePretax Income$7.0M

Learn while you research

Academy chapters picked for OptimizeRx Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →